UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

The lancet respiratory medicine, 2015-04, Vol.3 (4), p.301-309

2015

Volltextzugriff (PDF)

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

The lancet oncology, 2013-10, Vol.14 (11), p.1104-1111

2013

Volltextzugriff (PDF)

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

Cancer Immunology, Immunotherapy, 2015-08, Vol.64 (8), p.999-1009

2015

Volltextzugriff (PDF)

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Molecular oncology, 2011-04, Vol.5 (2), p.164-182

2011

Volltextzugriff (PDF)

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

Cancer Immunology, Immunotherapy, 2013-03, Vol.62 (3), p.605-614

2013

Volltextzugriff (PDF)

Armed antibodies for cancer treatment: a promising tool in a changing era

Cancer Immunology, Immunotherapy, 2015-01, Vol.64 (1), p.113-121

2015

Volltextzugriff (PDF)

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

Oncoimmunology, 2017-01, Vol.6 (7), p.e1323618-e1323618

2017

Volltextzugriff (PDF)

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9167-9171

2004

Volltextzugriff (PDF)

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

Journal of translational medicine, 2010-06, Vol.8 (1), p.56-56, Article 56

2010

Volltextzugriff (PDF)

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

Annals of the New York Academy of Sciences, 2012-10, Vol.1270 (1), p.8-12

2012

Volltextzugriff (PDF)

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

The lancet respiratory medicine, 2018-06, Vol.6 (6), p.451-460

2018

Volltextzugriff (PDF)

Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies

Seminars in oncology, 2015-06, Vol.42 (3), p.495-505

2015

Volltextzugriff (PDF)

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Clinical cancer research, 2019-12, Vol.25 (24), p.7351-7362

2019

Volltextzugriff (PDF)

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Cancer Immunology, Immunotherapy, 2019-09, Vol.68 (9), p.1547-1559

2019

Volltextzugriff (PDF)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

Future oncology (London, England), 2021-03, Vol.17 (9), p.1097-1104

2021

Volltextzugriff (PDF)

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Cancer Immunology, Immunotherapy, 2013-06, Vol.62 (6), p.1021-1028

2013

Volltextzugriff (PDF)

Immunotherapy targeting immune check-point(s) in brain metastases

Cytokine & growth factor reviews, 2017-08, Vol.36, p.33-38

2017

Volltextzugriff (PDF)

Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications

Seminars in oncology, 2010-10, Vol.37 (5), p.460-467

2010

Volltextzugriff (PDF)

Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma

International journal of dermatology, 2019-07, Vol.58 (7), p.e138-e140

2019

Volltextzugriff (PDF)

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Cancer Immunology, Immunotherapy, 2009-08, Vol.58 (8), p.1297-1306

2009

Volltextzugriff (PDF)

Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT270-CT270

2020

Volltextzugriff (PDF)

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

Endocrine, 2017-12, Vol.58 (3), p.535-541

2017

Volltextzugriff (PDF)

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4519-4519

2021

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(59)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Humans
(31)
Oncology
(24)
Melanoma
(20)
Male
(17)
Female
(15)
Immunotherapy
(15)
Melanoma - Drug Therapy
(13)
Middle Aged
(13)
Aged
(12)
Cancer Research
(12)
Immunology
(12)
Adult
(11)
Antibodies, Monoclonal - Therapeutic Use
(11)
Medicine
(11)
Medicine & Public Health
(11)
Clinical Trials
(9)
Dermatology
(9)
Ipilimumab
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

Armed antibodies for cancer treatment: a promising tool in a changing era

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Immunotherapy targeting immune check-point(s) in brain metastases

Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications

Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs)

Suchergebnisse filtern